MAP2K7 and cancer: Whereas direct RAS targeting has not allowed us to obtain a drug suitable for human use [23], in recent years a series of RAF and MEK specific inhibitors has been developed against several kinds of Ras/Raf/MEK/ERK-driven cancers [23].